The prevailing mantra of senior management regarding underwriting and most other operational functions is "faster, cheaper, better."
Chief underwriters are obliged to take whatever steps they can to address this in literally everything they oversee.
The success of simplified life products in the marketplace will be greatly impacted by how the premium rates match up against fully underwritten products.
Premium rates are tied to how the product is underwritten, because the less you know about the risk the more you have to charge to cover it.
This paper is the third comprehensive literature review on the cardiac marker NT-proBNP.
This new paper is based on 577 studies, reviews and commentaries published in the global medical literature between mid-2009 and March 2014.
It documents the length and breadth of the burgeoning evidence of NT-proBNP’s value as a screening and re exive test in life insurance underwriting.
Together with the NT-proBNP mortality study by Clark et al, this paper should put to rest any lingering questions or reservations in this regard.